Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...

Semaglutide linked to increased risk of nonarteritic anterior ischemic optic neuropathy, but evidence remains insufficient to establish definitive conclusion.

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Diabetic retinopathy is a leading cause of vision loss in working-age Indians. Doctor stresses that tight diabetes control, regular eye exams, and timely treatment can help protect sight from this ...

Palatin has a research program in DR, and more specifically, in diabetic macular edema (DME), a complication of DR that ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

The agreement with Palatin follows a $1bn deal with Re-Vana earlier this year as Boehringer targets the ophthalmology market.

Diabetic retinopathy and diabetic macular edema (DME) are two of the most common vision conditions related to diabetes. They affect about 1 in 4 people with type 1 and type 2 diabetes.

However, left untreated, diabetic retinopathy will steadily get worse over time and start to affect your vision. Treatment can help prevent, delay, and reduce vision loss.

Regarding diabetic retinopathy’s prevalence, , there are 40 million Americans who have diabetes, and about 60% of them of them will go on to get diabetic eye disease.

Diabetic retinopathy, a type of diabetic eye disease, is one of the leading causes of blindness in the United States. Despite this, almost 40% of people with diabetes don’t get an annual eye exam.

Hypertensive retinopathy and diabetic retinopathy are eye-related complications that can arise from high blood pressure or diabetes. Learn more about the two conditions here.